JNJ Shares Surge 53% Over Past Year on Drug Pipeline Momentum
Leerink Partners upgrades JNJ to Outperform with a $265 price target, citing revenue growth from new drugs. Johnson & Johnson’s shares have risen 53% over the past year and 15% year-to-date, driven by optimism around its drug pipeline. Leerink Partners upgraded the stock t